Bionomics Limited

ASX:BNO Stock Report

Market Cap: AU$14.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics Valuation

Is BNO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BNO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BNO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BNO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BNO?

Key metric: As BNO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BNO. This is calculated by dividing BNO's market cap by their current revenue.
What is BNO's PS Ratio?
PS Ratio2.4x
SalesAU$6.02m
Market CapAU$14.69m

Price to Sales Ratio vs Peers

How does BNO's PS Ratio compare to its peers?

The above table shows the PS ratio for BNO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.9x
ATX Amplia Therapeutics
5.6xn/aAU$24.7m
PAB Patrys
6.6xn/aAU$9.3m
IMC Immuron
3.5x59.7%AU$17.2m
ATH Alterity Therapeutics
4x25.0%AU$16.0m
BNO Bionomics
2.4x-5.3%AU$14.7m

Price-To-Sales vs Peers: BNO is good value based on its Price-To-Sales Ratio (2.4x) compared to the peer average (7.8x).

Price to Sales Ratio vs Industry

How does BNO's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.10.0x8.3%
BNO Bionomics
 2.4x-5.3%US$9.52m
ARX Aroa Biosurgery
3.6x20.1%US$142.40m
IMC Immuron
3.5x59.7%US$11.17m
BNO 2.4xIndustry Avg. 10.0xNo. of Companies8PS01632486480+
8 CompaniesEstimated GrowthMarket Cap
Industry Avg.10.0x15.3%
BNO Bionomics
 2.4x-36.0%US$9.52m
No more companies

Price-To-Sales vs Industry: BNO is good value based on its Price-To-Sales Ratio (2.4x) compared to the Australian Biotechs industry average (11.3x).

Price to Sales Ratio vs Fair Ratio

What is BNO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BNO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.4x
Fair PS Ratio0.2x

Price-To-Sales vs Fair Ratio: BNO is expensive based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.13

7D

0%

1Y

6.1%

AVITA Medical

US$339.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.92

7D

2.3%

1Y

25.0%

AVITA Medical

US$342.3m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.97

7D

0.3%

1Y

19.6%